secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001628280-23-039562
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Owen Hughes to board of directors
----------------------------------------------------------

- Owen Hughes appointed as Class I director, term until 2024 annual meeting.
- Hughes co-founded Cullinan Oncology, raised over $400M in IPO, served as CEO.
- Received options for 52,000 shares vesting over three years under 2020 plan.
- Indemnification agreement entered in same form as other directors.
- Hughes also chairs XOMA, Ikena Oncology; previously on boards of Radius, Translate Bio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023039562/0001628280-23-039562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023039562/cccc-20231120.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-039562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer